Keymed Biosciences, Inc. (HK:2162) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Keymed Biosciences Inc. has announced that China’s National Medical Products Administration approved its drug Stapokibart for treating chronic rhinosinusitis with nasal polyposis. The phase III clinical trial showed significant improvements in nasal polyp size and congestion, with a favorable safety profile. This approval marks a significant step for Keymed, showcasing its potential in the pharmaceutical market.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.